A Phase I Study Evaluating the Safety, Tolerability, PK and PD in Healthy Chinese Volunteers

PHASE1CompletedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

June 3, 2019

Primary Completion Date

November 6, 2019

Study Completion Date

November 6, 2019

Conditions

Healthy Chinese Volunteers

Interventions

DRUG

HBM9161(HL161BKN)

Subcutaneous injection; Single dose on Day 1

DRUG

Placebo

Subcutaneous injection; Single dose on Day 1

Trial Locations (1)

Queen Mary Hospital, Phase 1 Clinical Trials Centre, Hong Kong

All Listed Sponsors

lead

Harbour BioMed (Guangzhou) Co. Ltd.

INDUSTRY

NCT03971916 - A Phase I Study Evaluating the Safety, Tolerability, PK and PD in Healthy Chinese Volunteers | Biotech Hunter | Biotech Hunter